Although the nonspecific hyposensitization for nasal allergy has been clinically applied in the otorhinolaryngological field, the mechanism and the indication of this therapy has been not well known until the present time. In this present study, in order to clarify the indication of nonspecific hyposensitization therapy, clinical efficacy of this therapy for nasal allergy and laboratory findings of the patients with nasal allergy were retrospectively studied. The results obtained from this study were as follows;
(1) In the group of the adult patients treated with the combinated administration of Histaglobin (HG) 3-vials and Neurotropin (NSP) 1-Amp. per a week, the clinical efficacy rate was 76.2% (Adult group). Furthermore, in the group of the infant patients treated with HG 2-vials per a week, the clinical efficacy rate was 88.9% (Infant group).
(2) In the adult group, the patients whose serum IgE level were below 999 IU/ml in the pretreatment state showed some improved symptoms and clinical findings in comparison to those with serum IgE level above 1000 IU/ml. In the infant group, the patients with the score below 2 of skin reaction test showed some improved conditions in comparison to those with the score above 3.
(3) In the adult group, it was observed that the score of eosinophils in the nasal secretion significantly decreased in the considerably improved patients in the posttreatment state. In the infant group, the statistically significant increase of histaminopexic action, was noted in the considerably improved patients in the posttreatment state, also the significant increase of the score of the skin reaction test was noted in the same population.
From the above mentioned results, it was clarified that there were some differences between the clinical backgrounds of adults and infants with nasal allergy in reference with the clinical efficacy rate on the nonspecific hyposensitization therapy. For the infant patients, HG 2-vials therapy was considerably available to hyposensitize them nonspecifically. On the other hand, the combinated therapy of HG 3-vials and NSP 1-Amp. for the adult patients did not show high efficacy rate in comparison with the HG 2-vials therapy for the infants. Furthermore, it was suggested that a large amount of HG and NSP should be medicated in the adult patients with nasal allergy as the drugs of the nonspecific hyposensitization therapy.
View full abstract